The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’ Tafinlar + Mekinist, and, more recently, Pfizer / Array BioPharma’s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underpenetrated BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.

Questions Answered:

  • How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug treatment rates increase over the forecast period?
  • What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?
  • Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
  • What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?

Content Highlights

Geographies: United States, EU5, Japan.

Primary Research: 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and BRAF mutation status.

Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Emerging therapies: Phase III: 16 drugs; Phase II: 45 drugs; coverage of select preclinical and Phase I products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
    • Key Updates
      • May 2020
      • November 2019
      • August 2019
      • June 2019
      • March 2019
      • December 2018
    • Market Outlook
      • COVID-19: Areas of Potential Forecast Impact
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Malignant Melanoma?
        • What Factors Are Constraining the Market for Malignant Melanoma?
      • Segment-Specific Trends
        • Resectable Malignant Melanoma: Stage IIB-III
        • First-Line Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
        • First-Line Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
        • Previously Treated Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
        • Previously Treated Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Disease Pathophysiology
        • Progression of Malignant Melanoma
      • Staging and Classification
        • Classification and Staging of Malignant Melanoma
        • Histopathological and Clinical Prognostic Factors for Malignant Melanoma
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Malignant Melanoma
        • Recurrent Incident Cases on Malignant Melanoma
        • Drug-Treatable Populations of Malignant Melanoma
        • Drug-Treated Populations of Malignant Melanoma
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • BRAF / MEK Inhibitors
        • Oncolytic Viral Therapy
        • Cytokines
        • Cytotoxic Agents
      • Medical Practice
        • Drug-Treatable Populations
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Malignant Melanoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Therapeutic Vaccines
        • Intralesional Therapy
        • Angiogenesis Inhibitors
        • Cytokines
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Malignant Melanoma Bibliography

Author(s): Liseth M Parra, Ph.D; Oliver Blandy

Liseth M Parra,  is an analyst on the Oncology team at Decision Resources Group with an extensive background in oncology research and market analysis. Prior to joining DRG, Liseth generated valuable offerings and comprehensive strategic solutions for leading R&D clinical, commercial, and marketing teams in oncology as a research analyst for Kantar Health and as an independent consultant. Liseth holds a in neurobiology from the University of California, San Diego and completed a postdoctoral fellowship in oncology at the Brigham and Women’s hospital, Harvard Medical School. Liseth supports DRG’s syndicated oncology research offerings, focusing on malignant melanoma disease landscape and forecast analysis.

Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.


Related Reports

Malignant Melanoma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Malignant Melanoma | Current Treatment | Detailed, Expanded Analysis (US)

Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination...

View Details

Malignant Melanoma | Unmet Need | Detailed, Expanded Analysis: BRAF-Mutation-Positive, Unresectable or Metastatic Malignant Melanoma

Treatment of BRAF-mutation-positive unresectable or metastatic malignant mel...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2019

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both...

View Details